IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs. The company was founded in 2015 and is based in Daejeon, South Korea.
तुलना करने के लिए मीट्रिक्स | 287840 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध287840पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −59.0x | −21.5x | −0.4x | |
PEG अनुपात | −37.19 | −0.48 | 0.00 | |
क़ीमत/बुक | 25.3x | 3.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 272.3x | 23.3x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 0.0% | 58.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 21.5% | 9.2% | अनलॉक करें |